Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies

Theresa L Schwartz, Harveshp Mogal, Christos Papageorgiou, Jula Veerapong, Eddy C Hsueh, Theresa L Schwartz, Harveshp Mogal, Christos Papageorgiou, Jula Veerapong, Eddy C Hsueh

Abstract

Metaplastic breast cancer (MBC) is a rare subtype of invasive breast cancer that tends to have an aggressive clinical presentation as well as a variety of distinct histologic designations. Few systemic treatment options are available for MBC, as it has consistently shown a suboptimal response to standard chemotherapy regimens. These characteristics result in a worse overall prognosis for patients with MBC compared to those with standard invasive breast cancer. Due to its rarity, data focusing on MBC is limited. This review will discuss the clinical presentation, breast imaging findings, histologic and molecular characteristics of MBC as well as potential future research directions.

References

    1. Luini A, Aguilar M, Gatti G. et al.Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101:349–353. doi: 10.1007/s10549-006-9301-1.
    1. Tavassoli FA. Classification of metaplastic carcinomas of the breast. Pathol Annu. 1992;27(Pt 2):89–119.
    1. Fritz A, Percy C, Jack A, Solin LH. In International Classification of Diseases of Oncology 3. Geneva: World Health Organization; 2000.
    1. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: Prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–419. doi: 10.1023/A:1008329910362.
    1. Weigelt B, Kreike B, Reis-Filho JA. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117:273–280. doi: 10.1007/s10549-008-0197-9.
    1. Tse GM, Tan PH, Putti TC. et al.Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006;59:1079–1083. doi: 10.1136/jcp.2005.030536.
    1. Al Sayed AD, El Weshi AN, Tulbah AM. et al.Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol. 2006;45:188–195. doi: 10.1080/02841860500513235.
    1. Jung SY, Kim HY, Nam BH. et al.Worse prognosis of metaplastic breast cancer patients than other patients with triple negative breast cancer. Breast Cancer Res Treat. 2000;120:627–637.
    1. Okada N, Hasebe T, Iwasaki M. et al.Metaplastic carcinoma of the breast. Hum Pathol. 2010;41:960–970. doi: 10.1016/j.humpath.2009.11.013.
    1. Bae SY, Lee SK, Koo MY. et al.The prognoses of metaplastic breast cancer patients compared to those of triple negative breast cancer patients. Breast Cancer Res Treat. 2011;126:471–478. doi: 10.1007/s10549-011-1359-8.
    1. Kaufman MW, Marti JR, Gallager HS, Hoehn JL. Carcinoma of the breast with pseudosarcomatous metaplasia. Cancer. 1984;53:1908–1917. doi: 10.1002/1097-0142(19840501)53:9<1908::AID-CNCR2820530917>;2-F.
    1. Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg. 2006;191:657–664. doi: 10.1016/j.amjsurg.2006.01.038.
    1. Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol. 1999;71:220–225. doi: 10.1002/(SICI)1096-9098(199908)71:4<220::AID-JSO3>;2-L.
    1. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol. 1989;20:628–635. doi: 10.1016/0046-8177(89)90149-4.
    1. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol. 1989;20:732–740. doi: 10.1016/0046-8177(89)90065-8.
    1. Gutman H, Pollock RE, Janjan NA. et al.Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. J Am Coll Surg. 1995;180:193–199.
    1. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer. 1989;64:1490–1499. doi: 10.1002/1097-0142(19891001)64:7<1490::AID-CNCR2820640722>;2-L.
    1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer. 1969;63:181–187.
    1. Yang WT, Hennessy B, Broglio K, Mills C, Sneige N, Davis WG, Valero V, Hunt KK, Gilcrease MZ. Imaging differences in metaplastic and invasive ductal carcinomas of the breast. Am J Roentgenol. 2007;189:1288–1292. doi: 10.2214/AJR.07.2056.
    1. Shin HJ, Kim HH, Kim SM, Kim DB, Kim MJ, Gong G. et al.Imaging of metaplastic carcinoma with chondroid differentiation of the breast. Am J Roentgenol. 2007;188:691–696. doi: 10.2214/AJR.05.0831.
    1. Park JM, Han BK, Moon WK, Choe YH, Ahn SH, Gong G. Metaplastic carcinoma of the breast: Mammographic and sonographic findings. J Clin Ultrasound. 2000;28:179–186. doi: 10.1002/(SICI)1097-0096(200005)28:4<179::AID-JCU5>;2-Y.
    1. Brenner J, Turner RR, Schiller V, Arndt RD, Giuliano A. Metaplastic carcinoma of the breast: report of three cases. Cancer. 1998;82(6):1082–1087. doi: 10.1002/(SICI)1097-0142(19980315)82:6<1082::AID-CNCR11>;2-2.
    1. Gunhan-Bilgen I, Memis A, Ustun EE, Zekioglu O, Ozdemir N. Metaplastic carcinoma of the breast: clinical, mammographic and sonographic findings with histopathologic correlation. Am J Roentgenol. 2002;178:1421–1425. doi: 10.2214/ajr.178.6.1781421.
    1. Velasco M, Santamaría G, Ganau S, Farrús B, Zanón G, Romagosa C. et al.MRI of metaplastic carcinoma of the breast. Am J Roentgenol. 2005;184:1274–1278. doi: 10.2214/ajr.184.4.01841274.
    1. Park HS, Park S, Kim JH, Lee JH, Choi SY, Park BW, Lee KS. Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J. 2010;51(6):864–869. doi: 10.3349/ymj.2010.51.6.864.
    1. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg S, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Database. Ann Surg Onc. 2006;14(1):166–173. doi: 10.1245/s10434-006-9124-7.
    1. Chen IC, Lin CH, Huang CS, Lien HC, Hsu C, Kuo WH, Lu YS, Cheng AL. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011;130:345–351. doi: 10.1007/s10549-011-1686-9.
    1. Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17:605–613. doi: 10.1093/annonc/mdl006.
    1. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101:1174–1181. doi: 10.1093/jnci/djp235.
    1. Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma: rare form of mammary cancer. N Y State J Med. 1973;73:1078–1082.
    1. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2003. World Health Organization classification of tumors: tumors of the breast and female genital organs. Pathology and genetics of tumors of the digestive system; pp. 37–41.
    1. Ayar S, Dysee L, Carter E. Matrix-producing carcinoma: a rare variant of metaplastic breast carcinoma with heterologous elements. Breast J. 2010;16:420–423.
    1. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. V: Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol. 1990;21:1142–1150. doi: 10.1016/0046-8177(90)90151-T.
    1. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV: Squamous cell carcinoma of ductal origin. Cancer. 1990;65:272–276. doi: 10.1002/1097-0142(19900115)65:2<272::AID-CNCR2820650215>;2-6.
    1. Oberman HA. Metaplastic carcinoma of the breast. Am J Surg Pathol. 1987;11:918–929. doi: 10.1097/00000478-198712000-00002.
    1. Zhuang Z, Lininger RA, Man YG, Albuquerque A, Merino MJ, Tavassoli FA. Identical clonality of both components of mammary carcinosarcoma with differential loss of heterozygosity. Mod Pathol. 1997;10:354–362.
    1. George E, Manivel JC, Dehner LP, Wick MR. Malignant mixed Mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol. 1991;22:215–223. doi: 10.1016/0046-8177(91)90153-G.
    1. Chhieng C, Cranor M, Lesser ME, Rosen PP. Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. Am J Surg Pathol. 1998;22:188–194. doi: 10.1097/00000478-199802000-00006.
    1. Wada H, Enomoto T, Tsujimoto M, Nomura T, Murata Y, Shroyer KR. Carcinosarcoma of the breast: molecular-biological study for analysis of histogenesis. Hum Pathol. 1998;29:1324–1328. doi: 10.1016/S0046-8177(98)90266-0.
    1. Wang X, Mori I, Tang W. et al.Metaplastic carcinoma of thebreast: p53 analysis identified the same point mutation in the three histologic components. Mod Pathol. 2001;14:1183–1186. doi: 10.1038/modpathol.3880456.
    1. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21:292–300. doi: 10.1002/humu.10174.
    1. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci. 2000;910:121–137. discussion 137–139.
    1. Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 1998;77:1130–1136. doi: 10.1038/bjc.1998.187.
    1. DeCremoux P, Salomon AV, Liva S. et al.p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst. 1999;91:641–643. doi: 10.1093/jnci/91.7.641.
    1. Marchetti A, Buttitta F, Pellegrini S. et al.p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 1993;53:4665–4669.
    1. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 1992;355:846–847. doi: 10.1038/355846a0.
    1. Lien HC, Lin CW, Mao TL, Kuo SH, Hsiao CH, Huang CS. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol. 2004;204(2):131–139. doi: 10.1002/path.1624.
    1. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol. 2002;55(5):321–325. doi: 10.1136/jcp.55.5.321.
    1. Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997;57(23):5379–5385.
    1. Emoto M, Iwasaki H, Ishiguro M, Kikuchi M, Horiuchi S, Saito T, Tsukamoto N, Kawarabayashi T. Angiogenesis in carcinosarcomas of the uterus: differences in the microvesel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol. 1999;30(10):1232–1241. doi: 10.1016/S0046-8177(99)90043-6.
    1. Tanimoto H, Shigemasa K, Sasaki M, Katayama H, Kusumi I, Parmley TH, O’Brien TJ, Ohama K. Differential expression of matrix metalloprotease-7 in each component of uterine carcinosarcoma. Oncol Rep. 2000;7(6):1209–1212.
    1. Lien HC, Hsiao YH, Lin YS. et al.Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26:859–871. doi: 10.1038/sj.onc.1209840.
    1. Castilla MA, Diaz-Martin J, Sarrio D, Romero-Perez L, Lopez-Garcia A, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke C, Palacios J. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One. 2012;7(10):1–9.
    1. Hayes MJ, Thomas D, Emmons A, Giordano T, Kleer C. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008;14(13):4038–4044. doi: 10.1158/1078-0432.CCR-07-4379.
    1. Hennessy BT, Gonzalez-Angulo A-M, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee J-S, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–4124.
    1. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49(1):10–21. doi: 10.1111/j.1365-2559.2006.02467.x.
    1. Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelialdifferentiation? Immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol. 2005;29:347–353. doi: 10.1097/01.pas.0000152133.60278.d2.
    1. Dunne B, Lee AH, Pinder SE, Bell JA, Ellis IO. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol. 2003;34:1009–1015. doi: 10.1053/S0046-8177(03)00414-3.
    1. Popnikolov NK, Ayala AG, Graves K, Gatalica Z. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. Am J Clin Patho. 2003;120:161–167. doi: 10.1309/G6CTR8MDTFUW19XV.
    1. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M. et al.Distribution and significance of nerve growthfactor receptor (NGFR/p75 (NTR)) in normal, benign andmalignant breast tissue. Mod Pathol. 2006;19:307–319. doi: 10.1038/modpathol.3800542.
    1. Reis-Filho JS, Milanezi F, Paredes J, Silva P, Pereira EM, Maeda SA. et al.Novel and classic myoepithelial/stem cell markers inmetaplastic carcinomas of the breast. Appl Immunohistochem M M. 2003;11:1–8.
    1. Carter MR, Hornick JL, Lester S, Fletcher CDM. Spindle cell(sarcomatoid) carcinoma of the breast: a clinicopathologic andimmunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006;30:300–309.
    1. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT. et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–271. doi: 10.1038/modpathol.3800528.
    1. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z. et al.Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374. doi: 10.1158/1078-0432.CCR-04-0220.
    1. Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K. et al.Metaplastic breast carcinomas show EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res. 2005;7:1028–1035. doi: 10.1186/bcr1341.
    1. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative forHer-2 but frequently express EGFR (Her-1): potential relevance toadjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol. 2005;58:700–704. doi: 10.1136/jcp.2004.025163.
    1. Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F. et al.Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol. 2005;13:319–327. doi: 10.1177/106689690501300403.
    1. Reis-Filho JS, Pinheiro C, Lambros MB. et al.EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209:445–453. doi: 10.1002/path.2004.
    1. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene. 2000;19:6594–6599. doi: 10.1038/sj.onc.1204083.
    1. Calabrese C, Poppleton H, Kocak M. et al.A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69–82. doi: 10.1016/j.ccr.2006.11.020.
    1. Bellino R, Arisio R, D’Addato F. et al.Metaplastic breast carcinoma: Pathology and clinical outcome. Anticancer Res. 2003;23:669–673.
    1. Kochhar R, Howard EM, Umbreit JN. et al.Metaplastic breast carcinoma with squamous differentiation: Molecular and clinical analysis of six cases. Breast J. 2005;11:367–369. doi: 10.1111/j.1075-122X.2005.00031.x.
    1. Pantuck AJ, Zeng G, Belldegrun AS. et al.Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003;9:4641–4652.
    1. Del Bufalo D, Ciuffreda L, Trisciuoglio D. et al.Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer. 2006;66:5549–5554.
    1. Huynh H, Chow PK, Palanisamy N. et al.Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol. 2008;49:52–60. doi: 10.1016/j.jhep.2008.02.022.
    1. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011;29:e572–575. doi: 10.1200/JCO.2010.34.0604.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe